Dupixent (dupilumab) is the closest thing modern dermatology has to a silver-bullet for severe atopic dermatitis. It is also, for almost every Indian patient, financially destabilising. A typical adult on the licensed maintenance dose pays roughly ₹10–₹13 lakh per year out of pocket. Indian health insurance, with very few exceptions, does not cover it for eczema.
This is a transactional cost-and-access guide rather than a clinical one. The medical rationale for biologic therapy is covered in the Eczema in India pillar guide; the treatment ladder there ends with biologics and JAK inhibitors. What this article does is answer the questions that matter once a dermatologist has actually recommended Dupixent — how much it really costs in 2026, which insurers approve and which reject, what the Sanofi patient assistance programme actually delivers, and what cheaper alternatives are available to an Indian patient who simply cannot pay ₹13 lakh a year.
The Actual Price in 2026
| Product | Form | Indian MRP Range (2026) | Annual Adult Cost |
|---|---|---|---|
| Dupixent 300 mg pre-filled syringe | Subcutaneous | ₹40,000–₹55,000 | ₹10.4–₹14.3 lakh |
| Dupixent 200 mg pre-filled syringe (pediatric, lower-weight adults) | Subcutaneous | ₹30,000–₹42,000 | ₹3.9–₹5.5 lakh on 4-weekly schedule |
| Loading dose (2 × 300 mg on Day 1 for adults) | Subcutaneous | ₹80,000–₹1,10,000 one-time | — |
The licensed adult dosing schedule is a 600 mg loading dose followed by 300 mg every two weeks, indefinitely as long as the drug is working. That works out to 26 injections in the first year (one loading + 25 maintenance) and 26 injections each subsequent year on maintenance.
For a different non-steroidal eczema option that has just been launched globally and is starting to appear in Indian dermatology supply chains, see the Difamilast (Adquey) India guide — it sits at a much lower price point but is a topical PDE4 inhibitor rather than a systemic biologic, so the indication is different.
Pricing variation:
- Hospital pharmacy — typically the highest, often above MRP if billed with administration. Apollo, Max, Fortis and Manipal hospital pharmacies in 2026 commonly invoice ₹48,000–₹55,000 per syringe.
- Chain specialty pharmacy (Apollo retail, MedPlus Specialty, 1mg, Netmeds) — closer to MRP, often ₹42,000–₹48,000.
- Authorised Sanofi distributor cold chain — closer to ₹40,000–₹45,000 for patients on direct invoicing with the distributor, plus separate transport cold-chain charges in many cases.
- Sanofi patient assistance enrolment — historically a 25–50% reduction depending on tier and indication.
Cold chain handling is required (2 to 8°C). Self-pickup with thermal packing is possible; home delivery via Sanofi-authorised cold-chain logistics adds ₹500–₹1,500 per delivery in metro cities.
Indian Insurance Reality — Insurer-By-Insurer
This is where most patients lose money they did not have to lose. Indian health insurance product wordings interact with biologics in inconsistent ways. Patterns observed in the field as of 2026:
Insurers That Mostly Reject Dupixent for Eczema
- Star Health — eczema is not specifically excluded but biologic injectables for non-life-threatening conditions are commonly cited as outside policy intent. Rejection rate for eczema-only Dupixent claims is consistently high.
- Care Health Insurance (formerly Religare) — similar pattern. Pre-authorisation is rarely approved for atopic dermatitis alone.
- Older indemnity policies issued before 2018 — generally have day-care procedure lists that exclude biologic injections.
Insurers That Decide Case-By-Case
- HDFC Ergo — approval rate higher when there is documented failure of two systemic agents and the dermatologist explicitly cites EASI > 16. Some pre-authorisation approvals seen; better outcomes when the same Dupixent is used for severe asthma comorbidity.
- ICICI Lombard — relatively willing on its premium plans, more restrictive on basic plans.
- Niva Bupa (Max Bupa) — has approved Dupixent on several occasions, particularly on higher-end plans (Reassure 2.0, Health Premia). Documentation expectations are detailed — EASI scores, photographs, treatment history.
- Manipal Cigna ProHealth Prime — case-by-case, with documented approvals when severity criteria are clearly met.
Government and Group Plans
- CGHS, ECHS, ESI — approval is possible but slow, requires multiple committee clearances, and typically restricted to severe refractory cases at empanelled hospitals.
- Corporate group health plans — variable. Large IT and financial services companies sometimes have biologic riders that cover Dupixent at 70–100%; SME plans typically do not.
The general friction pattern across these insurers — slow pre-authorisation, repeated documentation requests, narrow interpretation of biologic clauses — is similar to the cashless-approval reality documented in the Max Hospital cashless insurance TPA speed guide. The same dynamics that delay routine cashless discharge by 8 to 14 hours also produce 3 to 6 week pre-authorisation delays on biologics.
For the broader pattern of insurance rejection on outpatient-leaning conditions, the analysis in the health insurance anxiety claim rejection guide covers an adjacent example — chronic conditions with strong outpatient components routinely fall into rejection zones in standard Indian policies. Dupixent for eczema sits in the same blind spot.
How to Apply for Sanofi’s Indian Patient Assistance
The Indian access pathway, as it stood in 2026, runs roughly as follows. Exact tiers and percentages change each fiscal year; this is the structural map.
Step 1 — Eligibility Documentation
Treating dermatologist provides:
- Written prescription specifying dupilumab, dose, indication
- EASI or SCORAD score documentation
- Severity photographs
- Documented failure or intolerance of prior topical and systemic therapy
- A medical-necessity letter
Patient provides:
- Income proof — recent salary slips or ITR
- ID proof, address proof
- Treatment history summary
Step 2 — Distributor or Hospital Pharmacy Enrolment
Submit the documentation through the treating dermatologist’s office to the authorised Sanofi distributor for the region or through a participating hospital pharmacy. Most large dermatology practices and tertiary centres are familiar with this process.
Step 3 — Tier Assignment
Sanofi or its partner foundation reviews the application and assigns a discount tier — historically 25%, 33% or 50% off MRP on maintenance doses. Loading doses are sometimes provided free or at a deep discount as a goodwill onboarding incentive.
Step 4 — Quarterly Re-evaluation
Most PAP tiers require quarterly clinical response data — updated EASI, photos, dermatologist sign-off — to continue. Patients who stop responding or who discontinue therapy fall out of the programme.
Practical Tips
- Apply through a dermatologist who has previously enrolled patients — they know the exact local distributor contact and current tier letter format.
- Submit clean and well-organised documentation in one go; back-and-forth requests delay enrolment by weeks.
- Combine PAP enrolment with a parallel insurance pre-authorisation push for the same indication — if insurance later approves, PAP eligibility may change.
Cheaper Alternatives — The Real Indian Stepping Stones
Before or instead of Dupixent, the practical options are:
Methotrexate
- Cost: ₹150–₹400/month (Folitrax, generic)
- Dose: 7.5–15 mg/week, oral, with folic acid 5 mg/week
- Onset: 8–12 weeks for full effect
- Pros: Cheap, decades of safety data, well-tolerated long-term
- Cons: Slow onset, requires CBC and LFT monitoring, contraindicated in pregnancy
Cyclosporine
- Cost: ₹2,500–₹4,500/month (Sandimmun, Imusporin)
- Dose: 2.5–5 mg/kg/day, oral
- Onset: 2–4 weeks (fastest of the conventional systemics)
- Pros: Fast control, useful as a bridge
- Cons: Limited to 6–12 months due to nephrotoxicity and hypertension risk; need monthly BP and creatinine checks
Upadacitinib (Indian Generic JAK1 Inhibitor)
- Cost: ₹6,000–₹12,000/month (Sun Pharma, Cipla, generic launches 2024–2025)
- Dose: 15 mg or 30 mg once daily oral
- Onset: 1–2 weeks
- Pros: Highly effective, oral, fast onset, much cheaper than Dupixent
- Cons: Boxed warnings for thrombosis, MACE, malignancy; not for high-risk patients; monthly bloodwork
Baricitinib
- Cost: ₹3,000–₹8,000/month (Lupin, Sun)
- Dose: 2 mg or 4 mg once daily oral
- Onset: 1–2 weeks
- Pros: Cheaper than upadacitinib, oral
- Cons: Similar JAK class warnings, monthly bloodwork
Direct Cost Comparison Per Year
| Option | Indian Cost / Year | Onset | Long-Term Use? |
|---|---|---|---|
| Topical + emollient + bleach baths | ₹15,000–₹40,000 | Days | Yes |
| Methotrexate | ₹2,000–₹5,000 | 8–12 weeks | Yes |
| Cyclosporine | ₹30,000–₹55,000 | 2–4 weeks | 6–12 months max |
| Baricitinib | ₹36,000–₹96,000 | 1–2 weeks | Yes, with monitoring |
| Upadacitinib | ₹72,000–₹1.4 lakh | 1–2 weeks | Yes, with monitoring |
| Dupilumab (Dupixent) full pay | ₹10.4–₹14.3 lakh | 4–8 weeks | Yes |
| Dupilumab with 50% PAP | ₹5–₹7 lakh | 4–8 weeks | Yes |
For a family priced out of Dupixent, the typical sequence is: optimise topicals and emollients → methotrexate → cyclosporine bridge → JAK inhibitor → only then consider biologic crowdfunding or PAP enrolment.
IRDAI Ombudsman Route — When You Have a Real Case
If you have documented severe disease, clear failure of cheaper options, a written medical-necessity letter from your dermatologist, and your insurer rejects Dupixent, the Insurance Ombudsman is a viable path:
- Internal grievance — File a written grievance with your insurer’s grievance officer. Insurers must respond within 14 days under IRDAI rules. If they delay or reject, you have grounds for escalation.
- Ombudsman complaint — File with the Office of the Insurance Ombudsman covering your region (Council for Insurance Ombudsmen). The process is free for claims up to ₹30 lakh.
- Documentation kit — Include EASI scores, treating dermatologist’s letter, treatment failure history, comparable approved cases if available, and the insurer’s rejection letter.
- Hearing — Conducted in person or virtually. Decisions are binding on insurers but not on the complainant.
Historical outcome pattern: ombudsman complaints succeed more often when (a) the policy wording does not explicitly exclude biologics, (b) the medical necessity is well documented, (c) cheaper alternatives have been tried and failed, and (d) the insurer’s rejection cites vague rather than specific clauses.
Practical Administration — What Your First Six Months Look Like
| Week | Event | Notes |
|---|---|---|
| 0 | Loading dose (600 mg = 2 × 300 mg syringes) | Usually administered at clinic under supervision |
| 2 | First maintenance (300 mg) | Often the second supervised dose; can move to home administration after this |
| 4, 6, 8 | Maintenance every 2 weeks | Home administration in pre-filled syringe |
| 8–16 | First major response window | Expect EASI 50% reduction by week 16 in good responders |
| 12 | First dermatology review | Photos, EASI, side effect check (especially conjunctivitis) |
| 16 | Major reassessment | Continue if EASI-50 achieved; reconsider if not |
| 24 | Mid-term review | Stable maintenance for good responders |
If your child is the patient, the first 2–3 administrations should always be supervised. Cold chain — syringes should be stored 2 to 8°C, allowed to reach room temperature for 30–45 minutes before injecting, never re-frozen.
When Dupixent Is Genuinely Worth It
For an Indian family considering whether to commit to Dupixent, the honest decision framework:
- EASI above 21, daily quality-of-life destruction, sleep loss, school or work disruption → strong case
- Documented failure of methotrexate or cyclosporine at adequate dose and duration → strong case
- Concomitant severe asthma, CRSwNP or eosinophilic oesophagitis → very strong case; one drug treats multiple conditions and insurance approval more likely
- Pediatric severe refractory eczema with growth or developmental impact → strong case despite cost
- Moderate eczema, EASI 7–15, not yet on adequate topical regimen → premature; optimise topicals, emollient, calcineurin inhibitor, climate triggers and water hardness first
- Adults already destabilised by topical steroid withdrawal → Dupixent can help but is not a substitute for the structured recovery protocol in the topical steroid withdrawal in India investigation
For severe eczema in India, Dupixent works. It just costs more than most insurance systems are willing to accept and more than most families can sustain. A clear-eyed plan with the right ladder of cheaper options first, careful PAP enrolment, and an ombudsman escalation if rejection is unfair is the realistic Indian access strategy.
Sources and References
- Sanofi India — Dupixent (dupilumab) prescribing information and Indian pricing schedule, 2026
- Sanofi Cares / Sanofi Patient Assistance Foundation — Indian access programme documentation
- US FDA — Dupixent label, pediatric expansion to 6 months and older
- European Medicines Agency — Dupixent summary of product characteristics
- Insurance Regulatory and Development Authority of India (IRDAI) — Grievance redressal rules and Insurance Ombudsman framework
- Council for Insurance Ombudsmen — Complaint filing process, cibcouncil.in
- Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) — Atopic dermatitis biologic position statement
- New England Journal of Medicine — Pivotal SOLO-1 and SOLO-2 trials of dupilumab in moderate-to-severe atopic dermatitis
- Lancet — Long-term efficacy and safety of dupilumab in adolescents and adults
- Indian generic JAK inhibitor pricing — Sun Pharma upadacitinib, Lupin and Sun baricitinib disclosures
Medical Disclaimer: This article is for informational purposes only and is not medical advice. The decision to start, continue or change biologic or systemic therapy must be made with a qualified dermatologist after individual clinical assessment. Pricing and patient assistance programme terms change frequently — verify current pricing with the treating dermatologist, an authorised Sanofi distributor or hospital pharmacy at the time of treatment. Insurance policy interpretations differ between insurers and individual plans — read your policy wording and confirm coverage in writing before commencing therapy. Reviewed by Fittour India Editorial Team in line with current Indian dermatology and insurance regulatory frameworks.